Ascent Wealth Partners 13F: Adds $1.6M to JNJ Stake

Ascent Wealth Partners increased its position in Johnson & Johnson JNJ, boosting its holdings by 204.5% during the period according to a Form 13F filed with the SEC on October 23, 2026. The firm acquired an additional 6,011 shares, bringing its total ownership to 8,951 shares valued at about $2.4 million.

JNJ Johnson & Johnson

$263.81 ▲ +29.27% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Ascent Wealth Partners's Johnson & Johnson Position

Ascent Wealth Partners grew its investment significantly by adding 6,011 shares to its prior count of 2,940 shares. The resulting stake of 8,951 shares carried a reported value of $2,369,688 as of the filing date. This move reflects a sharp increase of 204.5% from the previous quarter's holdings.

Other Institutional Activity in Johnson & Johnson

Other fund managers also adjusted their positions in the healthcare stock recently. SBI Securities grew its holdings by 10,021 shares, ending with 122,412 shares worth about $32.4 million. Accurate Wealth Management lifted its stake by 5,437 shares to finish with 37,817 shares valued at roughly $9.4 million. First Citizens Bank & Trust grew its holdings by 22,136 shares, resulting in 52,947 shares worth about $14.0 million. Capital Investment Advisors trimmed its position by 15,883 shares, leaving it with 398,735 shares valued at about $105.6 million. Meanwhile, BSN Capital Partners opened a new position by acquiring 282,000 shares worth about $75.9 million.

Johnson & Johnson Stock Up 2.4%

Johnson & Johnson shares recently traded around $263.85, sitting slightly above their 200-day moving average of $245.19. On the day of the filing, the stock closed at $263.81. The equity has moved between a 52-week low of $184.66 and a 52-week high of $281.07.

Recent Earnings

The company generated trailing twelve-month revenue of $99.3 billion with a net profit margin of 16.2% and year-over-year revenue growth of 5.9%. Its earnings per share over the same trailing period stood at $6.59. The next quarterly earnings report is scheduled for release on January 26, 2027.

Dividend

Johnson & Johnson provides an annual dividend of $5.36 per share, translating to a dividend yield of 2.0%. The payout is supported by a dividend payout ratio of 80.1%, reflecting the portion of earnings returned to investors through regular cash distributions.

Insider Buying and Selling at Johnson & Johnson

Several company insiders completed transactions prior to the filing date. Officer Elizabeth Forminard disposed of 15,918 shares valued at about $4.1 million on August 6, 2026. Chief Executive Officer Joaquin Boix Duato parted with 123,291 shares worth about $32.2 million on August 13, 2026. Officer Jennifer L. Taubert sold 15,000 shares at an average price of $263.36 for a total of nearly $4.0 million on August 17, 2026. Officer Timothy Schmid sold 33,597 shares at an average price of $274.74 for a total of $9.2 million on September 2, 2026.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. Leerink Partners maintained an outperform rating with a target of $272 on October 14, 2026, lowering it from $276. Wells Fargo maintained an overweight rating on October 14 with a $275 target, down from $282. RBC Capital maintained an outperform rating with a $280 target on October 14, lowering it from $290. Morgan Stanley maintained an overweight rating with a target of $292 on October 15, down from $294. Wells Fargo later maintained an overweight rating on October 16, raising its target to $287 from $275. Overall, the stock carries a consensus buy recommendation from 22 analysts with a mean target price of $279.41.

About Johnson & Johnson

Johnson & Johnson operates as a global healthcare enterprise that researches, develops, and manufactures a wide array of wellness products and medical solutions. The company operates primarily through two segments, Innovative Medicine and MedTech, serving patients and medical providers worldwide.

Bottom Line

Ascent Wealth Partners joins a diverse group of institutional managers adjusting their portfolios in the healthcare giant. Investors will watch for the company's next earnings release on January 26, 2027, to track ongoing revenue trends across its core operating segments.